Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pembrolizumab 11Fluorouracil 10Oxaliplatin 8Nivolumab 7Leucovorin 6Cisplatin 6Capecitabine 6Sorafenib 5Ipilimumab 5Cetuximab 5Bevacizumab 5Irinotecan 4trifluridine tipiracil drug combination 3trastuzumab deruxtecan 3durvalumab 3cabozantinib 3Trastuzumab 3Paclitaxel 3zolbetuximab 2trametinib 2sodium thiosulfate 2selpercatinib 2relatlimab 2lenvatinib 2larotrectinib 2encorafenib 2dabrafenib 2binimetinib 2X-Rays 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × lutetium Lu 177 dotatate × Gastrointestinal × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡